Clinical trial
A Dose-Ranging And Efficacy Study of LY2439821 (An Anti-IL-17 Antibody) In Patients With Moderate-To-Severe Psoriasis
The primary purpose for this study is to help answer the following research questions
- The safety of ixekizumab (LY2439821) and any side effects that might be associated with it.
- Whether ixekizumab can help participants with Psoriasis.
- How much ixekizumab should be given to participants.
| Category | Value |
|---|---|
| Date last updated at source | 2015-04-22 |
| Study type(s) | Interventional |
| Expected enrolment | 125 |
| Study start date | 2010-04-01 |
| Estimated primary completion date | 2018-06-01 |